Authors: Janiaud P, Axfors C, Schmitt AM, Glory V, Moher D PMID: 33635310 PMCID: PMC7911095 DOI: 10.1001/jama.2021.2747 Abstract Importance: Convalescent plasma is a proposed treatment for COVID-19. Objective: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs). [...]

Authors: Jalali F, Rezaie S, Rola P, Kyle-Sidell C doi: http://dx.doi.org/10.2139/ssrn.3800402 Abstract Established evidence suggests that in ARDS, platelets may exhibit a dysregulated state that exacerbates lung injury. We review evidence that suggests this platelet-mediated lung injury, while present in ARDS in general, is amplified in COVID-19 ARDS in particular. Driven by a quantifiably higher [...]

Authors: Patidar GK, Land KJ, Vrielink H, Dann EJ, Spitalnik SL PMID: 33730761 PMCID: PMC8250601 DOI: 10.1111/vox.13067 Abstract Background and objectives: Cytokine release syndrome in COVID-19 is due to a pathological inflammatory response of raised cytokines. Removal of these cytokines by therapeutic plasma exchange (TPE) prior to end-organ damage may improve clinical outcomes. This manuscript [...]

Authors: Zarehoseinzade E, Allami A, Ahmadi M, Bijani B PMID: 34169042 PMCID: PMC8214036 DOI: 10.47176/mjiri.35.30 Abstract Background: There is controversy about the efficacy of 5-alpha-reductase inhibitors in COVID-19 patients. Some assumed that finasteride might be a risk factor for deterioration and others proposed it as a possible adjunct treatment for moderate [...]

Authors: Pitt B, Sutton NR, Wang Z, Holinstat M PMID: 33667455 PMCID: PMC7923868 DOI: 10.1016/j.ejphar.2021.173988 Abstract There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a [...]

Authors: Supady A, Taccone FS, Lepper PM, Ziegeler S, Staudacher DL PMID: 33648538 PMCID: PMC7919616 DOI: 10.1186/s13054-021-03486-9 Abstract Survival of coronavirus disease 2019 (COVID-19) patients with severe respiratory failure treated with veno-venous extracorporeal membrane oxygenation (V-V ECMO) ranges around 60%, according to recent studies. Initial recommendations for the use of V-V [...]

Authors: Gordon AC, Mouncey PR, Rowan KM, Nichol AD, Arabi YM, Annane D PMID: 33631065 PMCID: PMC7953461 DOI: 10.1056/NEJMoa2100433 Abstract Background: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with [...]

Authors: Rosas IO, Brau N, Waters M, Go R, Hunter BD, Bhagani S et al. PMID: 33631066 PMCID: PMC7953459 DOI: 10.1056/NEJMoa2028700 Abstract Background: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in [...]

Authors: Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W PMID: 33632000 DOI: 10.1177/0885066621994057 Abstract Objectives: This study retrospectively compares the effectiveness of methylprednisolone to dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) requiring intensive care. Design: This is an institutional review board approved cohort study in patients with [...]

Uncertainty remains about how long the protective immune responses against severe acute respiratory syndrome coronavirus 2 persists, and suspected reinfection in recovered patients has been reported. We describe a case of reinfection from distinct virus lineages in Brazil harboring the E484K mutation, a variant associated with escape from neutralizing antibodies.